<DOC>
	<DOCNO>NCT01151644</DOCNO>
	<brief_summary>The prognosis rheumatic disease improve considerably development therapy . However , infection consider important cause morbidity mortality group patient . One way prevent complication vaccination . In 2009 , new pandemic strain influenza virus ( A/H1N1/2009 ) emerge raise major concern public health . Patients immunosuppressive therapy indication immunization influenza virus H1N1 . There , however , concern possibility reactivation autoimmune disease , determine adverse event insufficient immunogenicity patient . The lack study evaluate efficacy safety vaccine influenza A ( H1N1 ) /2009 rheumatic patient lead development research . The objective study evaluate humoral response safety vaccine virus A ( H1N1 ) /2009 immunosuppressed patient rheumatic disease compare healthy control . We recruit 400 patient rheumatoid arthritis , 350 spondyloarthritis , 1000 systemic lupus erythematosus ( SLE ) , 150 dermatomyositis ( DM ) , 100 mixed connective tissue disease , 150 systemic vasculitis , 250 systemic sclerosis ( SSc ) , 100 Sjögren 's syndrome , 100 antiphospholipid syndrome , 100 patient juvenile idiopathic arthritis , 80 juvenile SLE , 80 juvenile DM , follow Rheumatology Outpatient Division Unit Pediatric Rheumatology Children 's Institute , HC-FMUSP . The control group recruit 200 healthy employee ICHC-FMUSP . Informed consent obtain participant study approve Local Ethical Committee . All subject vaccinate influenza virus A/ ( H1N1 ) /2009 ( vaccine approve supplied Instituto Butantan-São Paulo ) . Blood sample collect measure level antibody inhibit hemagglutination influenza virus A ( H1N1 ) /2009 immediately prior vaccination 21 28 day vaccination. , Participants fulfil questionnaire immediate side effect vaccine . All patient rheumatoid arthritis , spondyloarthritis , SLE , DM , systemic vasculitis , juvenile idiopathic arthritis , juvenile SLE , DM assess 21 day vaccination clinical , laboratory parameter disease activity well treatment . Continuous variable compare t-test evaluate difference patient rheumatic disease versus healthy control . Differences categorical variable evaluate use chi-square Fisher exact test . Statistical significance set p &lt; 0.05 .</brief_summary>
	<brief_title>Safety Efficacy Anti-Pandemic H1N1 Vaccination Rheumatic Diseases</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Rheumatic disease accord international criterion disorder Previous confirm infection virus A ( H1N1 ) /2009 History anaphylatic reaction egg component Acute fever GuillainBarré syndrome , heart failure ( class III IV ) , demyelinate disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>H1N1 VACCINE</keyword>
	<keyword>INFLUENZA</keyword>
	<keyword>RHEUMATIC DISEASES</keyword>
	<keyword>ANTI-H1N1 IMMUNIZATION</keyword>
</DOC>